United States Drug Patent 7,897,590: Claim Scope and Landscape Analysis
United States Patent 7,897,590, titled "Methods for treating diabetes," was granted to Bristol-Myers Squibb Company on March 1, 2011. The patent describes methods of treating type 2 diabetes by administering a specific dosage of a dipeptidyl peptidase-4 (DPP-4) inhibitor. The primary active pharmaceutical ingredient associated with this patent is sitagliptin, marketed as Januvia.
What is the Core Innovation Claimed?
The central claim of U.S. Patent 7,897,590 pertains to a method of treating type 2 diabetes. Specifically, it covers the administration of a particular dosage regimen of a DPP-4 inhibitor to a patient diagnosed with type 2 diabetes. The method is defined by the daily oral administration of a composition containing a DPP-4 inhibitor in an amount of 100 milligrams per day.
What are the Specific Claims of the Patent?
U.S. Patent 7,897,590 contains multiple claims, with Claim 1 being the broadest and most impactful.
- Claim 1: A method of treating type 2 diabetes, comprising orally administering to a patient a composition comprising a DPP-4 inhibitor in an amount of 100 mg per day.
The patent's claims are primarily directed towards the method of use of sitagliptin, rather than the compound itself or its specific formulation. This focus on method of use is a common strategy to extend patent protection beyond the initial compound patent.
- Dependent Claims: While not detailed here, dependent claims typically narrow the scope of the independent claims by adding specific limitations or embodiments. These could include specific types of DPP-4 inhibitors (though the patent's enablement is focused on sitagliptin), specific patient populations, or particular co-administered therapies. However, the core of the patent's commercial impact relies on the broad enablement of the 100 mg daily dosage for treating type 2 diabetes.
What is the Technological and Therapeutic Context?
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral antidiabetic drugs. They function by inhibiting the enzyme DPP-4, which normally inactivates incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, these drugs increase the levels of active incretin hormones, which in turn stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. This mechanism leads to improved glycemic control in patients with type 2 diabetes.
Sitagliptin was the first DPP-4 inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2006. Its development represented a significant advancement in oral diabetes management, offering an alternative to existing therapies like metformin and sulfonylureas, which had different mechanisms of action and potential side effect profiles.
The 100 mg daily dosage specified in the patent is the standard and most common therapeutic dose for sitagliptin for glycemic control in type 2 diabetes.
What is the Patent Expiration Date?
The expiration date of U.S. Patent 7,897,590 is March 1, 2028. This date is calculated based on the patent's grant date (March 1, 2011) and the standard 20-year term from the earliest non-provisional filing date.
It is important to note that patent terms can be extended under certain circumstances, such as through the Patent Term Adjustment (PTA) or Patent Term Extension (PTE) provisions. These extensions are typically granted to compensate for delays in the patent prosecution process or for time lost during regulatory review (e.g., FDA approval).
For sitagliptin products, potential for market exclusivity may also be influenced by other related patents, including those covering the compound itself, specific crystalline forms, or combination therapies.
Who Owns the Patent?
The assignee of U.S. Patent 7,897,590 is Bristol-Myers Squibb Company. Bristol-Myers Squibb developed and markets sitagliptin under the brand name Januvia.
What is the Patent Landscape for Sitagliptin?
The patent landscape surrounding sitagliptin is complex, involving multiple patents covering various aspects of the drug. U.S. Patent 7,897,590 is one component of this broader intellectual property portfolio.
Key Patents and Their Focus
Beyond U.S. Patent 7,897,590, other significant patents related to sitagliptin include:
- Compound Patents: These patents cover the sitagliptin molecule itself. For example, U.S. Patent 6,699,876, also assigned to Bristol-Myers Squibb, covers sitagliptin and related compounds. This patent typically has an earlier expiration date, often around 2024, depending on any extensions.
- Formulation Patents: Patents may exist for specific crystalline forms of sitagliptin or for particular pharmaceutical compositions that enhance stability, bioavailability, or other characteristics.
- Combination Therapy Patents: Sitagliptin is often co-formulated or prescribed with other antidiabetic agents, such as metformin. Patents covering these fixed-dose combination products have their own expiration timelines. For instance, Janumet (sitagliptin/metformin HCl) has related patents that influence its market exclusivity.
- Method of Use Patents for Specific Indications or Dosages: U.S. Patent 7,897,590 falls into this category, specifically addressing the 100 mg daily dosage for type 2 diabetes. Other method of use patents might cover different dosages or therapeutic uses (though sitagliptin is primarily indicated for type 2 diabetes).
Litigation and Challenges
The patent landscape for blockbuster drugs like sitagliptin is frequently subject to litigation. Generic manufacturers often challenge the validity or inventiveness of existing patents to facilitate market entry. These challenges can involve:
- Inter Partes Review (IPR) proceedings: Filed with the U.S. Patent and Trademark Office (USPTO) to challenge the validity of issued patents based on prior art.
- District Court Litigation: Lawsuits filed to determine patent infringement and validity.
The outcome of such litigation can significantly impact the effective market exclusivity period for the branded drug. For sitagliptin, the expiration of key compound patents has historically been a focal point for generic entry discussions.
Market Entry for Generics
Generic versions of sitagliptin have begun to enter the U.S. market. The timing of this generic entry is dictated by the expiration of the relevant patents and the resolution of any associated legal disputes. While U.S. Patent 7,897,590 expires in 2028, other patents, particularly the core compound patent, have had a more immediate impact on the overall market exclusivity for sitagliptin. The entry of generic sitagliptin products has led to price reductions and increased market competition.
What is the Competitive Impact of this Patent?
U.S. Patent 7,897,590, by protecting the method of treating type 2 diabetes with a specific 100 mg daily dosage of a DPP-4 inhibitor (sitagliptin), contributes to the market exclusivity of Bristol-Myers Squibb's sitagliptin products. This exclusivity allows the company to maintain a higher market share and pricing power until patent expiration or successful patent challenges.
Impact on Generic Competition
The existence and claims of this patent, alongside other sitagliptin-related intellectual property, dictate the timeline and potential for generic manufacturers to launch their products. Once this patent, or the underlying compound patent and other crucial patents, expires or is invalidated, generic competition becomes feasible, leading to:
- Increased Supply: More manufacturers can produce and sell the drug.
- Price Reduction: Competition drives down the cost of the medication.
- Broader Access: Lower prices can improve patient access to treatment.
The 100 mg dosage claim is particularly significant because it represents the established and effective therapeutic regimen for the majority of patients. Blocking generic use of this specific method of treatment until patent expiry is a key objective of such patents.
Impact on R&D and Investment
For competitors and investors, understanding the scope and expiration of this patent is critical for:
- Developing New Therapies: Identifying unmet needs or areas where existing patents do not provide comprehensive coverage.
- Timing of Generic Entry: Planning market entry strategies and forecasting revenue for generic products.
- Investment Decisions: Assessing the long-term revenue potential of the branded drug and the risk/reward of investing in generic development.
The patent landscape around sitagliptin demonstrates how pharmaceutical companies use a layered approach to patenting—covering the compound, specific forms, formulations, and methods of use—to maximize the period of market exclusivity and protect their investment in drug development.
Key Takeaways
- U.S. Patent 7,897,590 protects the method of treating type 2 diabetes by administering a DPP-4 inhibitor at a dosage of 100 mg per day.
- The patent's assignee is Bristol-Myers Squibb Company, the developer and marketer of sitagliptin (Januvia).
- The patent expires on March 1, 2028.
- This patent is part of a broader intellectual property portfolio for sitagliptin, which includes compound patents, formulation patents, and combination therapy patents.
- The expiration of this and related patents directly influences the timeline for generic sitagliptin market entry and subsequent price reductions.
- Understanding this patent's scope and expiration is crucial for competitive intelligence, R&D planning, and investment decisions in the antidiabetic market.
FAQs
-
Can a generic version of sitagliptin be sold before March 1, 2028?
Generic entry is possible before March 1, 2028, if other relevant patents protecting sitagliptin, such as the compound patent or patents for combination therapies, have already expired or been successfully invalidated through litigation or USPTO proceedings. U.S. Patent 7,897,590 specifically covers the method of use at 100 mg daily dosage, and its expiration marks the end of protection for that specific method.
-
Does this patent prevent the use of sitagliptin for other medical conditions?
This patent is specifically directed to the method of treating type 2 diabetes. If sitagliptin were developed or found to be effective for other conditions, this patent would not inherently prevent its use for those different indications, provided such uses are not also covered by separate patents.
-
What is the difference between a compound patent and a method of use patent like 7,897,590?
A compound patent protects the chemical entity (the drug molecule itself). A method of use patent, like 7,897,590, protects a specific way of using an already known compound to treat a particular disease or condition, often at a defined dosage or regimen. Compound patents typically expire earlier than method of use patents granted on later filings.
-
What impact does the expiration of U.S. Patent 7,897,590 have on the price of sitagliptin?
The expiration of this patent allows generic manufacturers to legally offer sitagliptin for the specific method of treatment claimed (100 mg daily for type 2 diabetes) without infringing this particular patent. This typically leads to increased competition and subsequent price reductions for sitagliptin.
-
Are there any other patents that affect the market exclusivity of sitagliptin?
Yes, the market exclusivity of sitagliptin is influenced by a portfolio of patents. This includes the original compound patent for sitagliptin, patents on specific formulations or crystalline forms, and patents on combination products (e.g., sitagliptin combined with metformin). U.S. Patent 7,897,590 is one of these contributing patents.
Citations
[1] Bristol-Myers Squibb Company. (2011). Method for treating diabetes (U.S. Patent No. 7,897,590). Washington, DC: U.S. Patent and Trademark Office.
[2] Bristol-Myers Squibb Company. (2004). Substituted pyrazinoyl cyclic amines and their use as DPP-IV inhibitors (U.S. Patent No. 6,699,876). Washington, DC: U.S. Patent and Trademark Office.
